Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer

The concept of using biological information from tumours to determine treatment approaches is not new as this is routinely done for breast cancers (among others), and testing for the hormonal receptor status of these tumours has become routine. Because a number of studies have indicated that immunoh...

Full description

Saved in:
Bibliographic Details
Published in:Gut 2006-06, Vol.55 (6), p.759-761
Main Author: Carethers, J M
Format: Article
Language:English
Subjects:
5-fluorouracil
Antimetabolites, Antineoplastic - therapeutic use
Base Pair Mismatch - genetics
Cancer therapies
Chemotherapy
Clinical medicine
Colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Confidence intervals
Deoxyribonucleic acid
DNA
DNA Repair - genetics
DNA, Neoplasm - genetics
Fluorouracil - therapeutic use
Humans
Medical prognosis
mismatch repair system
Mutation
Patient Selection
prognosis
Proteins
Studies
treatment
Treatment Outcome
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The concept of using biological information from tumours to determine treatment approaches is not new as this is routinely done for breast cancers (among others), and testing for the hormonal receptor status of these tumours has become routine. Because a number of studies have indicated that immunohistochemistry of MMR proteins is a good surrogate for determining the MMR status of colorectal tumours, 24, 25 this testing, which can be done by any pathology laboratory service, needs to become commonplace as studies such as the one highlighted in this issue of Gut determine that this information will guide the most optimal care of patients.
ISSN:0017-5749
1468-3288
DOI:10.1136/gut.2005.085274